Bifogade filer
Devyser wins tender in Sweden for Thalassemia NGS testing worth up to 8.4 million SEK
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Devyser has secured a tender for its NGS product, Devyser Thalassemia, which is designed for screening and confirmation of thalassemia, a hereditary blood disorder. The tender, with a prestigious University Hospital in Stockholm, is for two years with the possibility of a two-year extension. The estimated annual order value of the tender is approximately 2.1 million SEK.
"The prevalence of thalassemia has increased in Western Europe, prompting hospitals to enhance their patient testing protocols. Winning this tender marks our strong position in the Scandinavian market for thalassemia, and I am very proud of the team that made this possible," says CEO Fredrik Alpsten. "This tender underscores the competitiveness and high quality of Devyser Thalassemia."
Thalassemia is a hereditary blood disorder associated with mild to severe anemia, bone problems, and slow growth in children. An estimated 5.2 percent of people carry a thalassemia-causing genetic mutation. Devyser Thalassemia, an end-to-end solution for screening and confirmation of thalassemia, gives users a comprehensive genetic profile for thalassemia gene clusters with a fast turnaround time and minimal hands-on time. The NGS workflow is suitable for any lab, whether running advanced genetic testing or large-scale mutation screening.